Histone 'reader' protein helps block prostate cancer metastasis

MD Anderson scientists have identified a protein that could prevent metastasis in prostate cancer, as shown in mouse models and cell-line experiments.

“For metastasis, cancer cells acquire migratory and invasive abilities and so gaining new insight into how this occurs and how to stop metastasis is crucial. We believe this study opens a window into this process,” said Min Gyu Lee, an associate professor of molecular and cellular oncology, in a statement.

The study focused on histones, proteins that play a role in gene regulation. Some histone modifications have affected gene expressions that have been associated with cancer progression. The researchers examined the protein ZMYND8, which, as a histone “reader,” can recognize these histone changes, potentially influence gene expression and head off metastasis.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“It has been well documented that the effects of histone acetylation and methylation on gene expression can be mediated by specific binding proteins called ‘readers,’” Lee said. “We identified ZMYND8 as a reader for histone marks called H3K4me1 and H3K14ac, both of which are tied to metastasis-linked genes.”

The researchers also found that ZMYND8 worked with a histone modification “eraser” called JARID1D and successfully blocked metastasis-linked genes, they said in the statement. While Lee’s team previously discovered that metastasized prostate tumors had lower JARID1D levels than normal prostate and primary prostate tumors, the new study exposed the metastasis-blocking action of ZYMND8 in tandem with JARID1D.

Other work on prostate cancer metastasis include that of the Lawrence Livermore National Laboratory and the University of California. Researchers found that sclerostin, a protein secreted in bone, prevents prostate cancer from metastasizing in bone.

- here's the statement
- here's the study abstract

Related Articles:
Brigham researchers demonstrate a systemic Trojan Horse approach for prostate cancer
Roche bags a preclinical next-gen prostate cancer program in $142M deal
Experimental prostate cancer combo shows promise in case studies

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.